Home › Targets › CD20
CD20 (4 companies · 14 programs)
Companies with an active program directed at CD20.
- AlloNK — Rheumatoid Arthritis Phase 1
- AlloNK — Sjögren's Disease Phase 2
- AlloNK — Systemic Sclerosis Phase 2
- AlloNK — Idiopathic Inflammatory Myopathies Phase 2
- AlloNK — Systemic Lupus Erythematosus Phase 1
- AlloNK — Lupus Nephritis Phase 1
- AlloNK — Pemphigus Vulgaris Phase 1
- AlloNK — ANCA-Associated Vasculitis Phase 1
- BRIUMVI — Relapsing Forms of Multiple Sclerosis Approved
- BRIUMVI — Myasthenia Gravis Phase 1
- ublituximab — Relapsing Forms of Multiple Sclerosis Phase 3
- plamotamab — Rheumatoid Arthritis Phase 1
- JNJ-1493 — B-Cell Lymphoma Phase 1
